Recent Quotes

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-05
REV		(EXPECTED)2021-08-05

Q1 2021		Est.		Actual		Surprise
EPS		-0.320		-0.310		0.0100
REV				0

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
ORTX	Orchard Therapeutics	4.85	0.00	0%		600.3M

Orchard Therapeutics Frequently Asked Questions

How do I buy Orchard Therapeutics (ORTX) stock?

You can purchase shares of Orchard Therapeutics (NASDAQ: ORTX) through any online brokerage.

View our list of the best stock brokerages.

Who are Orchard Therapeutics's (ORTX) competitors?

Other companies in Orchard Therapeutics’s space includes: KalVista Pharmaceuticals (NASDAQ:KALV), TCR2 Therapeutics (NASDAQ:TCRR), Atossa Therapeutics (NASDAQ:ATOS), Altimmune (NASDAQ:ALT) and AnaptysBio (NASDAQ:ANAB).

What is the target price for Orchard Therapeutics (ORTX) stock?

The latest price target for Orchard Therapeutics (NASDAQ: ORTX) was reported by JP Morgan on March 2, 2021. The analyst firm set a price target for 15.00 expecting ORTX to rise to within 12 months (a possible 209.28% upside). 2 analyst firms have reported ratings in the last year.

Current Stock Price for Orchard Therapeutics (ORTX)?

The stock price for Orchard Therapeutics (NASDAQ: ORTX) is $4.85 last updated Today at 8:00:02 PM.

Does Orchard Therapeutics (ORTX) pay a dividend?

There are no upcoming dividends for Orchard Therapeutics.

When is Orchard Therapeutics (NASDAQ:ORTX) reporting earnings?

Orchard Therapeutics’s Q2 earnings are confirmed for after-market on August 5, 2021.

Is Orchard Therapeutics (ORTX) going to split?

There is no upcoming split for Orchard Therapeutics.

What sector and industry does Orchard Therapeutics (ORTX) operate in?

Orchard Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.